Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Incidence of Chronic spontaneous urticaria
7 evidence topics · 6 sources
United States: incidence of diagnosed CSU in three US databases, 2012 to 2018, Novartis-funded
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incident cohorts included newly identified patients with the first urticaria or angioedema code within the year of interest and no codes 12 months prior to that year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Optum EHR, the age- and sex-standardized incidence rate (95% CI) among adults and pediatric patients during the identification period was 0.039 (0.039–0.039) and 0.066 (0.065–0.067) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-standardized incidence rate (95% CI) of CSU among the adult and pediatric populations during the identification period in Optum CDM was 0.094 (0.093–0.095) and 0.109 (0.107–0.111) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In MarketScan, the age-standardized incidence rate (95% CI) of CSU among adults and pediatric patients during the identification period was 0.102 (0.097–0.107) and 0.097 (0.096–0.098) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study also reports for the first time, to the best of our knowledge, standard incidence rate of diagnosed CSU in the USA, with period estimates among adults ranging from 0.039 to 0.102 per 100 person-years in the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: combined adult and pediatric incidence of diagnosed CSU and annual trend, Novartis-funded study
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.096 (0.096–0.097) per 100 person-years and 0.283% (0.281–0.284), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.088 (0.087–0.088) per 100 person-years and 0.244% (0.243–0.245), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual incidence rate ranged from 0.031 in 2012 to 0.069 per 100 person-years in 2018 across the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparatively, the incidence and prevalence were higher among pediatric patients than adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: average annual incidence of diagnosed CSU of 0.08% in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual incidence rate was 0.08%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: chronic urticaria incidence estimate in the Joint Task Force practice parameter
Italy: incidence of CSU in a general practitioner database, 2002 to 2013
“The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual prevalence and incidence rates of CSU over a 12-year period (2002-2013) were estimated, along with demographic and clinical determinants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence was 0·10-1·50 per 1000 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For both prevalence and incidence rates, female patients outnumbered male.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italy: incidence of newly diagnosed CSU in primary care, 2002 to 2022
“A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence was 2.07-1.93 per 1000 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A cohort of 7,018 patients with CSU was identified during the study period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global: urticaria incidence in the Global Burden of Disease 2021 study
“We utilized data from the Global Burden of Disease (GBD) Results (2021) to obtain prevalence, incidence, and disability-adjusted life years (DALYs) for urticaria from 1990 to 2021, categorized by age, gender, and region.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regarding incidence, the total number of urticaria cases rose from 84,870,288 (74,471,430 − 96,206,256) in 1990 to 117,014,587 (104,106,688 − 131,017,656) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence rate declined from 1591.23 (1396.26-1803.77) per 100,000 population in 1990 to 1482.82 (1319.25-1660.27) in 2021, with an EAPC value of 0.01 (0.01–0.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As shown in Fig. 1 , across all age groups, females generally have higher incidence and DALYs compared to males.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Projections indicate a continued rise through 2046.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Region | Age-standardized incidence rate, 1990 | Age-standardized incidence rate, 2021 |
|---|---|---|
| High-income North America | “1569.62 (1461.56-1669.2)”View highlighted excerpt for this quote | “1602.35 (1507.35-1697.23)”View highlighted excerpt for this quote |
| Global | “1529.24 (1355.9-1720.36)”View highlighted excerpt for this quote | “1533.71 (1358.35-1726.07)”View highlighted excerpt for this quote |